What the 1 ml volume in a Wegovy pen actually tells you

The decision most people are trying to make: is my pen normal?

If you have searched for "Wegovy 1 ml pen" you are probably holding a pen and wondering whether it looks right. That is a completely reasonable thing to check, and the honest answer is that a 1 ml fill is correct for every Wegovy strength currently available. The solution should appear clear and colourless. A tiny air bubble is harmless and normal in any pre-filled injector. What would not be normal: visible particles, cloudiness, or a colour that looks pink or yellow. If you see any of those, do not inject, contact your prescriber or pharmacist.

The pen is designed so the dose is set automatically. There is no dial, no plunger to judge, and no way to alter the amount delivered by pressing harder or softer. More on what a single Wegovy pen delivers explains this automatic mechanism in plain terms. Your Patient Information Leaflet is the authoritative reference for step-by-step injection technique; if you have mislaid it, the Mounjaro and Wegovy SmPCs on the electronic Medicines Compendium host the full document for every licensed strength.

Concentration versus volume: why the 1 ml figure is the same on every pen

Novo Nordisk supplies Wegovy in a fixed 1 ml cartridge regardless of the dose. The way a higher dose is achieved is by increasing the concentration of semaglutide dissolved in that millilitre, not by increasing the fill. So a 0.25 mg pen and a 2.4 mg pen both contain 1 ml of liquid, but the 2.4 mg pen has roughly ten times more active medicine per millilitre. This is standard pharmaceutical practice for pre-filled injection devices.

It also means the visible liquid level in the window looks similar across strengths, which can be confusing if you are comparing pens from different months of your titration. A dedicated page on Wegovy pen volume walks through the concentration figures for each dose. If you want to understand exactly how the ml measurement relates to each Wegovy pen, that detail is covered alongside the concentration figures for every available strength. For context on how the titration schedule works (starting at 0.25 mg and rising through 0.5, 1.0, 1.7 and 2.4 mg over roughly five months) the NHS semaglutide medicines page sets this out clearly. Dose changes are always decided by your prescriber; they are not something to adjust on your own schedule.

Injection site, storage, and the 1 ml pen in practice

The 1 ml volume has a practical implication for storage. Wegovy pens must be kept refrigerated between 2°C and 8°C until first use. Once you have used the first dose from a pen, the remaining doses in that same pen can be stored at room temperature for a limited period, but the exact window is stated in your Patient Information Leaflet, and that is the figure to follow, not any approximation. Do not freeze the pen. Keep it away from light. Guidance on injection sites covers the recommended areas (abdomen, thigh or upper arm) and why rotating them matters.

After each use, replace the pen cap and dispose of the needle safely. A 1-litre sharps container is the appropriate way to discard used needles at home, and most GP surgeries and pharmacies accept sharps bins for collection. Do not put needles in household recycling. If you are curious about the physical dimensions of the device you are using, our page on the Wegovy 1.5 ml pen explains how fill volumes are specified across the product range. If you are approaching your final dose from a pen, remember that the next pen needs to come out of the fridge in good time, but not so early that it exceeds the room-temperature window.

Side effects worth knowing before you inject

Most people starting or stepping up their Wegovy dose notice gastrointestinal effects: nausea, loose stools, constipation, or a general feeling of fullness that arrives earlier than expected. These are the body adjusting to semaglutide slowing gastric emptying. For most, they settle within a couple of weeks of each new dose level. Eating smaller portions, staying well hydrated, and avoiding very fatty meals can all help.

A less common but more serious concern is pancreatitis. The MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as a known, infrequent but serious risk with GLP-1 medicines: if you develop severe abdominal pain that spreads to your back (particularly if it does not ease and comes with vomiting) seek urgent medical help and do not inject your next dose until you have spoken to a clinician. Any suspected side effects can be reported directly at the MHRA Yellow Card scheme. For a broader look at available weight-loss injection options, the treatment overview covers what is currently licensed in the UK. If you have questions about starting Wegovy through a regulated private pharmacy, speaking to our prescribers is the place to begin.